Option chain shows key data for TG Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TG Therapeutics.

TG Therapeutics (NASDAQ:TGTX) Stock, Option Chain

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

A Different Picture

News

Guidance

Movers

TGTX

TG Therapeutics Inc (NASDAQ:TGTX) shares are trading higher. The company on Tuesday provided guidance for the fourth quarter and full-year 2024. 

What&#39;s Going On With TG Therapeutics Stock Tuesday?

movers image

Pre-Market Outlook

Markets

Trading Ideas

ALAR

ATSG

CSWC

EDSA

EFSH

NLSP

NSSC

NUWE

OKLO

OMIC

SIFY

STAF

VSTE

YUMC

Why Yum China Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

Apple, Nio, CVS Health, Stellantis, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Napco Security Technologies Posts Downbeat Results, Joins Centrus Energy, Constellation Energy And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

TG Therapeutics Inc

Press Releases

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Earnings

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

TG Therapeutics to Participate in the Evercore HealthCONx Conference

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Nuvalent

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

HC Wainwright & Co.

JP Morgan

Goldman Sachs

TD Cowen

B. Riley Securities

Comments

TG Therapeutics

TG Therapeutics (TGTX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga